MDisrupt

Women’s Health Is Finally Getting the Attention It Deserves—Here’s the Proof At MDisrupt, we’re seeing a surge in demand for OBGYN expertise from healthtech companies. Just this past month, 15+ healthtech companies have come to us looking to connect with OBGYNs to help shape their products. But that’s not the only shift we’re seeing. These companies are also proactively seeking insights from payers—a clear sign that more healthtech innovators are thinking about reimbursement strategies from day one. The best part? Clinicians’ voices—especially OBGYNs—are being considered earlier in product development. This is exactly how we build health products that scale in healthcare: by involving healthcare stakeholders early and often. Women’s health innovation is accelerating, and this time, it’s happening with the right expertise at the table. ??

What’s on the Minds of Health System Executives? Health system leaders are making their priorities clear for 2025–2030, and healthtech companies should be paying attention. A recent survey of CEOs and Chief Strategy Officers highlights the biggest challenges they’re focused on: ? Navigating regulatory changes – Adapting to evolving policies while ensuring operational efficiency. ? Integrating advanced technologies – AI, telemedicine, and digital tools are high on their radar, but implementation remains a challenge. ? Addressing workforce challenges – Staffing shortages and burnout continue to put pressure on care delivery. ? Enhancing patient experience – A shift toward more personalized, accessible, and tech-driven care. ? Building collaborative partnerships – Health systems are looking for innovative solutions that fit within their existing infrastructure and demonstrate measurable impact. For healthtech innovators, the message is clear: Getting health system adoption isn’t just about having great technology—it’s about solving real challenges and proving value. Where do you see the biggest opportunity for health tech to drive impact in the next five years?

A new?BCG report?projects that the women’s health market will grow from?$5 billion today to as much as $27 billion by 2030. But more importantly, it highlights just how much?unmet need still exists?across the sector. Key areas driving this growth: ??Pharmaceuticals?($19B) ??Consumer Health Products?($1B–$3B) ??Digital Services (telehealth, symptom trackers, etc.)?($1B–$5B) ??Wearables & Medical Technology?($300M) Despite the momentum,?women’s health has long been underfunded and underserved—from clinical trials to payer coverage and beyond. As more companies, investors, and healthcare leaders focus on closing these gaps, the big question is:?Where should we be prioritizing innovation? What do you think is the biggest opportunity in women’s health right now?

Payer reimbursement in healthtech isn’t just tough—it’s a long, complex process. Even the most promising healthtech innovations face challenges when it comes to reimbursement. That’s because the healthcare system wasn’t designed for new technologies. It’s a maze of regulations, payer priorities, and shifting financial models that can be difficult to navigate. Some of the biggest hurdles? ? Understanding the right codes – CPT, HCPCS, DRG—without them, reimbursement isn’t even on the table. ? Proving value to payers – Clinical effectiveness isn’t always enough; payers want to see cost savings and real-world outcomes. ? Navigating different reimbursement models – Fee-for-service, value-based care, and employer-sponsored plans all work differently. ? The long timeline – Even with FDA clearance, payer adoption can take years. Healthtech companies don’t need to figure this out alone. The right expertise—especially from those who’ve worked inside payer organizations—can make all the difference. At MDisrupt, we connect healthtech innovators with the experts who know how to build successful payer strategies. If reimbursement is on your roadmap, we can help. Want to learn more? Let’s talk.

Today The American Heart Association published this statement on Direct-to-Consumer Genetic Testing for Cardiovascular Disease: The AHA emphasizes that while Direct-to-Consumer (DTC) genetic testing can provide valuable insights into cardiovascular risk, it should be interpreted with caution and ideally integrated into clinical care with the guidance of healthcare professionals. Key recommendations include: 1. Healthcare Provider Involvement: ???? Consumers should consult genetic counselors or healthcare providers to interpret results accurately. ???? Physicians should be equipped with knowledge or resources to assist patients in understanding genetic findings. 2. Regulatory Oversight & Accuracy: ???? Greater regulation and standardization are needed to ensure the clinical validity and utility of DTC tests. ???? Confirmatory testing and family history assessment are critical before making any medical decisions. 3. Patient Education & Ethical Considerations: ???? Consumers should be aware of the limitations, privacy concerns, and potential psychological impact of genetic results. ???? DTC companies should ensure transparent communication about what their tests can and cannot reveal. https://lnkd.in/gT6zfa_h For companies innovating in this area MDisrupt can help in the following ways - Adding cardiologists to your teams and advisory boards - Help design tests with the appropriate specificity and sensitivity - Navigate the regulatory landscape - Build engaging products and reports that both providers and their patients can accept.

AI in Healthcare: Transformative or Troubling? Erik Wexler, CEO of Providence, recently called a meeting with OpenAI?one of the most important he’s had in years. AI has the potential to?reduce clinician burden, streamline workflows, and improve patient care—but it also raises big questions. On one hand, AI could help doctors and nurses by?automating note-taking, managing inboxes, and even easing the prior authorization process.?On the other, Wexler warns it could lead to an?arms race between payers and providers, each leveraging AI to navigate the complex (and costly) healthcare system. Clinicians are already wary—more than half report concerns that AI is increasing prior authorization denials?rather than reducing them. The takeaway??AI in healthcare isn’t a silver bullet, but it does have the potential to drive meaningful change—if implemented thoughtfully, with collaboration between innovators, providers, and policymakers.

Vendor fatigue isn’t going anywhere. And Health Systems and Payers continue to tell us what a huge problem it is for them. And if you are a digital health company - its the hidden hurdle for adoption and reimbursement. The webinar we hosted last year with Melissa Reilly, Zeev Neuwirth, MD and Toyin Falola, MD tackled why so many digital health solutions struggle to gain traction—and the insights they shared are just as relevant today. Here’s what our expert panel unpacked: - Clinical outcomes matter—big time. If you want adoption, clinical validation isn’t optional. Engaging clinicians early helps build the evidence needed to succeed. - Tech that doesn’t fit real-world workflows? Hard pass. If your solution doesn’t solve the actual, day-to-day challenges clinicians face, expect pushback. - Payers don’t all think alike. Some prioritize cost savings, others focus on revenue or care delivery. Know your audience and tailor your pitch accordingly. Watch the replay here: https://lnkd.in/g2sNABuP

Big news in digital health: Hinge Health has officially filed for an IPO! This is a major milestone—not just for Hinge, but for the entire sector. It signals that investors still see opportunity in digital health, even in a challenging funding environment. But here’s the bigger picture: - Are digital health companies proving ROI? Health systems and payers are more selective than ever. - What does it take to scale? Hinge’s journey shows that clinical validation, payer traction, and strong distribution channels are key. - Who’s next? With several late-stage digital health companies waiting in the wings, this could be the start of a new wave of public exits.

We are excited to announce that Susan Solinsky has joined MDisrupt’s Board of Directors! As a serial co-founder, investor, advisor, and operating partner in numerous digital health companies and investment firms, Susan brings a wealth of experience in scaling healthtech companies, executing high-impact go-to-market strategies, and driving commercial success. She is also a passionate advocate for women’s health, ensuring innovative solutions reach the people who need them most. Susan joins the board alongside Lisa Suennen and Cat Hernandez, further strengthening MDisrupt’s leadership as we work to bridge the gap between healthtech and healthcare. Her expertise will be instrumental as we continue to expand our platform and accelerate our mission. Please join us in welcoming Susan to the MDisrupt team!

At MDisrupt, We Knew the Value of Chief Medical Officers Long Ago The role of Chief Medical Officers (CMOs) is no longer just a checkbox for credibility—it’s a critical function driving healthcare innovation. As highlighted in this Business Insider article, some of the world’s top companies, from Google to Uber to Salesforce, are recognizing the need for physicians in executive leadership. At MDisrupt, we understood this long ago. We’ve built a marketplace of healthcare insiders—physicians, payor executives, regulatory leaders, and clinical strategists—who help healthtech companies de-risk their products, validate their solutions, and navigate the complexities of the healthcare ecosystem. The takeaway? Healthtech innovation isn’t just about building great technology. It’s about building with healthcare expertise from the start. That’s exactly what we do at MDisrupt. https://lnkd.in/gvNDnB6G